Concepedia

Peey‐Sei Kok

PK

Statistics

Publications

12

Citations

622

H-Index

11

Active since

2017

Affiliations

National Health and Medical Research Council(Current)

The University of Sydney

Chris O’Brien Lifehouse

The University of Queensland

Sir Charles Gairdner Hospital

Peey‐Sei Kok is an author at National Health and Medical Research Council specializing in oncology, medicine, and chemotherapy.

ORCID

Publications per year

2017–2022

12

Publications

12

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

Anna K. Nowak, W. Joost Lesterhuis, Peey‐Sei Kok et al. · The Lancet Oncology · 2020 · 169 citations · Full text

, , +12

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial

Yoland Antill, Peey‐Sei Kok, Kristy Robledo et al. · Journal for ImmunoTherapy of Cancer · 2021 · 129 citations · Full text

, , +13

Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).

Yoland Antill, Peey‐Sei Kok, Kristy Robledo et al. · Journal of Clinical Oncology · 2019 · 55 citations

, , +11

Pre‐ and on‐treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer

Angelina Tjokrowidjaja, Sarah J. Lord, Thomas John et al. · Cancer · 2022 · 45 citations · Full text

, , +17

OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result

Anna K. Nowak, Peey‐Sei Kok, W. Joost Lesterhuis et al. · Journal of Thoracic Oncology · 2018 · 42 citations · Full text

, , +9

1–5 of 12